Terapia Fotodinamica (PDT)



Controllo spazio-temporale

Terapia Fotodinamica (PDT)





si valuta che $^1O_2$ possa diffondere per un raggio ca. 45 nm dal punto in cui viene generato.


Singlet excited state PS (PDT)
Long-lived
triplet excited state PS (PDT)
Fluorescence (Imaging)
Phosphorescence (Imaging)
Potential energy
Inter-atomic distance
S1
T1
S0
PS*
PS*
PS
kISC
hν
2hν
knr
kf
kP
PS photosensitizer
Sn singlet states
Tn triplet states
hν one photon absorption
2hν two photon absorption
ISC intersytem crossing
nr non-radiative decay
PS ground state PS

Tissue penetration of light



PDT window

ΔE between $^1O_2$ and $^3O_2$ = 94 kJ/mol

This energy gap is compatible with photosensitizers that have absorption maxima up to over 800 nm (their triplet excited state is still higher in energy than the ground state of $^3O_2$.

The ideal photosensitizer

- Absorbs strongly in the PDT window (600 – 900 nm)
- Has a high $^1O_2$ quantum yield
- Is photostable (no photo-bleaching)
- Is non-toxic in the dark
- Localizes selectively in the diseased tissue
- Has a rapid clearance

Macrocicli tetrapirrolici come PS

22π 600 – 650nm

18π 700 – 800nm

20π 630 – 700nm

Porphyrin

a



Chlorin

b



Bacteriochlor

c



Phthalocyanine

d



Fotosensibilizzatori per PDT di prima e seconda generazione

λ = 652
ε = 3×10^4 M^{-1}cm^{-1}



λ = 630
ε = 1170 M^{-1}cm^{-1}


Foscan


Photochlor


Talaporfin sodium


Visudyne


Purlytin


Lutrin


Tookad



Photosens

Tumori della pelle non-pigmentati: ALA-PDT

acido 5-aminolevuleico





Photofrin



Foscan



Photochlor



Talaporfin sodium



Visudyne



Purlytin



Lutrin



Tookad



Photosens



TOOKAD-solubile

(palladio-batteriofeoforbide)

azione prevalente a livello vascolare











degenerazione maculare senile

First line treatment









Fotosensibilizzatori per PDT di terza generazione (*targeted*)



IgG conjugated chlorin



HIV-1 Tat peptide conjugated porphyrin



Glycoconjugated chlorin (H_2TFPC-SGlc)



Folate conjugated temoporfin

Tumor margin resection with *tumor avid* PS's



Brain tumor, patient treated with Foscan



Blue light

Site-activated constructs



Derivati del BODIPY (*boron-dipyrromethene)*







Photoactivatable metal compounds



Diagrammi semplificati degli MO di frontiera e degli stati di $[Ru(bpy)_3]^{2+}$



Metal compounds for PDT



Health Canada Approves Clinical Trial Application for Anti-Cancer Drug

Toronto, Ontario – December 17, 2015, Theralase Technologies Inc. ("Theralase" or the "Company") (TLT:TSXV) (TLTFF:OTC), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that Health Canada has approved its next generation anti-cancer drug, TLD-1433, under Clinical Trial Application ("CTA") for evaluation in a Phase Ib clinical trial for patients inflicted with Non-Muscle Invasive Bladder Cancer ("NMIBC").



In vitro studies



TLD1433, Dark EC_{50} > 300 µM

TLD1433, Red EC_{50} = 7.20 ± 1.10 µM

$[Os(dmb)_2(IP\text{-}3T)]Cl_2$, Dark EC_{50} = 242 ± 3 µM

$[Os(dmb)_2(IP\text{-}3T)]Cl_2$, Red EC_{50} = 18.4 ± 0.1 µM


2+
S
S
S
H
N
N
N
N
N
N
N
N
Ru

TLD1433


Percent Survival
100
50
0
20
40
60
80
100
Days Post Treatment
TLD1433 + light
TLD1433, no light
Light only, no TLD1433

Elementi di design molecolare



Aumentare la coniugazione π di un legante diiminico fa diminuire l'energia dello stato eccitato ^{3}IL (*intraligand*), con conseguente aumento del suo tempo di vita e maggior produzione di $^1O_2$.


5.0
3.0
2.0
1.0
Energy (eV)
^1GS
^1IL
^1MLCT
^3MLCT
^3ILCT
^3IL
(dark)
for
THERAPY
(emissive)
for DIAGNOSIS
and IMAGING
electron
transfer
reactions
$^1O_2$
$^3O_2$
Cl2
Ru
N
H
S
TLD1433

Dati 2020

Table 1. PDT agents in clinical use or in clinical trials[a].

Class	PDT agent	Metal	Stage	Excitation (nm)	Area	Cancer type
Protoporphyrin IX precursor	5-Aminolevulinic acid (Levulan®)		FDA approved	635	Global	Skin, brain, oesophagus
	Methyl aminolevulinate (Metvix®)		FDA approved	635		Skin
	Hexyl 5-aminolevulinate (Hexvix®)		FDA approved	380–450 (diagnosis)		Bladder
Porphyrin derivatives	Porfimer sodium (Photofrin®)		FDA approved	630	Global	Lung, bladder, oesophagus, bile duct, brain
	Photogem		MHRF approved	660	Russia	Respiratory and digestive tracts, urogenital
Chlorin derivatives	Temoporfin (Foscan®)		EMA approved	652	EU	Head and neck, bile duct, lung
	Ce6-PVP (Fotolon®)		Phase 2	660–670	Germany	Lung
	Radachlorin®		MHRF approved	662	Russia	Skin
	Talaporfin sodium (Laserphyrin®)		MHLW approved	664	Japan	Lung, brain
	HPPH (Photochlor®)		Phase 2	665	USA	Lung, oral cavity, oesophagus
Bacteriochlorin derivatives	Redaporfin		Phase 2	749	Portugal	Head and neck
Phthalocyanine derivatives	Silicon phthalocyanine (Pc4)		Phase 1	672	USA	Skin
Metal complex	Padoporfin (TOOKAD®)	Pd	Terminated	763	EU	Prostate
	Padeliporfin potassium (TOOKAD® Soluble)	Pd	EMA approved	753	EU	Prostate
	TLD-1433	Ru	Phase 2	520	Canada	Bladder, brain
	Motexafin lutetium (Antrin®)	Lu	Terminated	732	USA	Breast, prostate
	Rostaporfin (Purlytin®)	Sn	Phase 2/3	664	USA	Breast, bile duct, ovarian, colon

[a]Data from clinicaltrials.gov.